Payment overview · 2025
General Payments
$372.74
21 reported records · 10 companies
Healthcare provider profile · identity verified
Jerome Anthony Dixon, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CAMPBELLSVILLE, KY · NPI 1215919451
Verified facts
What the public records show
CMS Open Payments records show Jerome Anthony Dixon, D.O. received $372.74 in general payments during 2025 across 21 reported records.
Vanda Pharmaceuticals Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trintellix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.10 | 28.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.96 | 16.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.15 | 15.1% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $30.26 | 8.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.30 | 7.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.04 | 7.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.73 | 4.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.14 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.41 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.65 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.74 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $105.10 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $60.96 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.15 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.04 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $28.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 93 |
| Eliquis | Apixaban | 496 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 487 | 88 |
| Gabapentin | Gabapentin | 393 | 59 |
| Potassium Chloride | Potassium Chloride | 351 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 63 |
| Memantine Hcl | Memantine Hcl | 298 | 34 |
| Famotidine | Famotidine | 288 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 61 |
| Omeprazole | Omeprazole | 275 | 56 |
| Furosemide | Furosemide | 269 | 40 |
| Donepezil Hcl | Donepezil Hcl | 267 | 32 |
| Montelukast Sodium | Montelukast Sodium | 261 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 45 |
| Metformin Hcl | Metformin Hcl | 245 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 243 | 48 |
| Sucralfate | Sucralfate | 212 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 205 | 21 |
| Sertraline Hcl | Sertraline Hcl | 183 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 182 | 39 |
| Losartan Potassium | Losartan Potassium | 165 | 28 |
| Meloxicam | Meloxicam | 159 | 28 |
| Lorazepam | Lorazepam | 145 | 26 |
| Lisinopril | Lisinopril | 136 | 25 |
| Tramadol Hcl | Tramadol Hcl | 136 | 44 |
| Carvedilol | Carvedilol | 132 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 40 |
| Irbesartan | Irbesartan | 131 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 30 |
| Mirtazapine | Mirtazapine | 120 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 17 |
| Prednisone | Prednisone | 114 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 18 |
| Baclofen | Baclofen | 107 | 21 |
| Buprenorphine Hcl | Buprenorphine Hcl | 103 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 15 |
| Myrbetriq | Mirabegron | 95 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 95 | 16 |
| Ezetimibe | Ezetimibe | 93 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 23 |
| Simvastatin | Simvastatin | 85 | 19 |
| Divalproex Sodium | Divalproex Sodium | 82 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 16 |
| Ramipril | Ramipril | 81 | 12 |
| Bumetanide | Bumetanide | 80 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 15 |
| Pregabalin | Pregabalin | 78 | 15 |
| Buspirone Hcl | Buspirone Hcl | 74 | 14 |
| Xarelto | Rivaroxaban | 73 | suppressed |
| Digoxin | Digoxin | 69 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 12 |
| Nystatin | Nystatin | 68 | 28 |
| Farxiga | Dapagliflozin Propanediol | 65 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 11 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Azithromycin | Azithromycin | 62 | 47 |
| Sotalol | Sotalol Hcl | 62 | suppressed |
| Spironolactone | Spironolactone | 58 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | 12 |
| Metformin Hcl Er | Metformin Hcl | 55 | 11 |
| Valsartan | Valsartan | 54 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 54 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Acetic Acid | Acetic Acid | 50 | 12 |
| Diazepam | Diazepam | 50 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 50 | suppressed |
| Allopurinol | Allopurinol | 49 | 13 |
| Finasteride | Finasteride | 47 | 13 |
| Fluconazole | Fluconazole | 47 | 31 |
| Risperidone | Risperidone | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Estradiol | Estradiol | 45 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 13 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 40 | suppressed |
| Cefdinir | Cefdinir | 40 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 21 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 26 |
| Atenolol | Atenolol | 36 | 11 |
| Primidone | Primidone | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 14 |
| Ozempic | Semaglutide | 34 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 33 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Otezla | Apremilast | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 18 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Motegrity | Prucalopride Succinate | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 20 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 11 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 11 |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.74 · 21 records | Vanda Pharmaceuticals Inc. | BREZTRI, CAPLYTA, FANAPT, FARXIGA, JARDIANCE, Kerendia, REXULTI, SUBLOCADE, TRINTELLIX, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error